Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …
tremendous success in treating cancer, although success still remains limited to a fraction of …
Top 10 challenges in cancer immunotherapy
Cancer immunotherapy is a validated and critically important approach for treating patients
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …
Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity
Epigenetic dysregulation is a defining feature of tumorigenesis that is implicated in immune
escape,. Here, to identify factors that modulate the immune sensitivity of cancer cells, we …
escape,. Here, to identify factors that modulate the immune sensitivity of cancer cells, we …
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
PD-1 blockade has transformed the management of advanced clear cell renal cell
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely …
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely …
Targeting the HIF2–VEGF axis in renal cell carcinoma
TK Choueiri, WG Kaelin Jr - Nature medicine, 2020 - nature.com
Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …
Beyond conventional immune-checkpoint inhibition—novel immunotherapies for renal cell carcinoma
The management of advanced-stage renal cell carcinoma (RCC) has been transformed by
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …
[HTML][HTML] Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors
V Leko, SA Rosenberg - Cancer Cell, 2020 - cell.com
Cancer elimination in humans can be achieved with immunotherapy that relies on T
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …
Alternative tumour-specific antigens
The study of tumour-specific antigens (TSAs) as targets for antitumour therapies has
accelerated within the past decade. The most commonly studied class of TSAs are those …
accelerated within the past decade. The most commonly studied class of TSAs are those …
Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer
WG Kaelin - The Journal of Clinical Investigation, 2022 - Am Soc Clin Investig
Germline loss-of-function mutations of the VHL tumor suppressor gene cause von Hippel–
Lindau disease, which is associated with an increased risk of hemangioblastomas, clear cell …
Lindau disease, which is associated with an increased risk of hemangioblastomas, clear cell …